Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 435

1.

Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson's disease.

Arribarat G, Pasternak O, De Barros A, Galitzky M, Rascol O, Péran P.

Parkinsonism Relat Disord. 2019 May 22. pii: S1353-8020(19)30254-8. doi: 10.1016/j.parkreldis.2019.05.033. [Epub ahead of print]

PMID:
31182373
2.

A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control.

Nemmi F, Pavy-Le Traon A, Phillips OR, Galitzky M, Meissner WG, Rascol O, Péran P.

Neuroimage Clin. 2019 May 13;23:101858. doi: 10.1016/j.nicl.2019.101858. [Epub ahead of print]

3.

Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.

Delamarre A, Tison F, Li Q, Galitzky M, Rascol O, Bezard E, Meissner WG.

J Neural Transm (Vienna). 2019 Jun;126(6):789-793. doi: 10.1007/s00702-019-02015-x. Epub 2019 May 16.

PMID:
31098725
4.

How to diagnose parkinsonian central pain?

Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, Durif F, Brefel-Courbon C.

Parkinsonism Relat Disord. 2019 May 1. pii: S1353-8020(19)30220-2. doi: 10.1016/j.parkreldis.2019.04.025. [Epub ahead of print]

PMID:
31072757
5.

Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?

Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B; NS-Park/F-CRIN Network study group.

Parkinsonism Relat Disord. 2019 Apr 25. pii: S1353-8020(19)30207-X. doi: 10.1016/j.parkreldis.2019.04.012. [Epub ahead of print]

PMID:
31047798
6.

French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS).

Marques A, Vidal T, Pereira B, Benchetrit E, Socha J, Pineau F, Elbaz A, Artaud F, Mangone G, You H, Cormier F, Galitstky M, Pomies E, Rascol O, Derkinderen P, Weintraub D, Corvol JC, Durif F; DIGPD study group.

Parkinsonism Relat Disord. 2019 Mar 4. pii: S1353-8020(19)30072-0. doi: 10.1016/j.parkreldis.2019.02.026. [Epub ahead of print]

PMID:
30862454
7.

Reversible myoclonus-ataxia encephalitis related to anti-mGLUR1 autoantibodies.

Gollion C, Dupouy J, Roberts M, Simonetta-Moreau M, Brefel Courbon C, Rascol O, Honnorat J, Magne FO.

Mov Disord. 2019 Mar;34(3):438-439. doi: 10.1002/mds.27634. Epub 2019 Feb 13. No abstract available.

PMID:
30759326
8.

Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type.

Vergnet S, Hives F, Foubert-Samier A, Payoux P, Fernandez P, Meyer M, Dupouy J, Brefel-Courbon C, Ory-Magne F, Rascol O, Tison F, Pavy-Le Traon A, Meissner WG.

Parkinsonism Relat Disord. 2019 Feb 5. pii: S1353-8020(19)30037-9. doi: 10.1016/j.parkreldis.2019.02.006. [Epub ahead of print]

PMID:
30745212
9.

Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.

Pérez-Lloret S, Quarracino C, Otero-Losada M, Rascol O.

Expert Opin Pharmacother. 2019 Apr;20(6):635-645. doi: 10.1080/14656566.2019.1574746. Epub 2019 Feb 7. Review.

PMID:
30730771
10.

Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P.

Eur J Neurol. 2019 Jul;26(7):953-960. doi: 10.1111/ene.13914. Epub 2019 Mar 25.

11.

CVT-301 for Parkinson's disease: dose and effect size issues.

Rascol O.

Lancet Neurol. 2019 Feb;18(2):128-130. doi: 10.1016/S1474-4422(18)30496-4. No abstract available.

PMID:
30663600
12.

Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations.

Pavy-Le Traon A, Cotterill N, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Tison F, Wenning GK, Goetz CG, Poewe W, Sampaio C, Schrag A, Rascol O, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 Oct 25;5(5):479-491. doi: 10.1002/mdc3.12636. eCollection 2018 Sep-Oct. Review.

PMID:
30515437
13.

Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease.

Cormier-Dequaire F, Bekadar S, Anheim M, Lebbah S, Pelissolo A, Krack P, Lacomblez L, Lhommée E, Castrioto A, Azulay JP, Defebvre L, Kreisler A, Durif F, Marques-Raquel A, Brefel-Courbon C, Grabli D, Roze E, Llorca PM, Ory-Magne F, Benatru I, Ansquer S, Maltête D, Tir M, Krystkowiak P, Tranchant C, Lagha-Boukbiza O, Lebrun-Vignes B, Mangone G, Vidailhet M, Charbonnier-Beaupel F, Rascol O, Lesage S, Brice A, Tezenas du Montcel S, Corvol JC; BADGE-PD study group.

Mov Disord. 2018 Dec;33(12):1878-1886. doi: 10.1002/mds.27519. Epub 2018 Nov 16.

PMID:
30444952
14.

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Charvin D, Medori R, Hauser RA, Rascol O.

Nat Rev Drug Discov. 2018 Nov;17(11):844. doi: 10.1038/nrd.2018.184. Epub 2018 Oct 12.

PMID:
30310231
15.

Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.

Corvol JC, Durif F, Meissner WG, Azulay JP, Haddad R, Guimarães-Costa R, Mariani LL, Cormier-Dequaire F, Thalamas C, Galitzky M, Boraud T, Debilly B, Eusebio A, Houot M, Dellapina E, Chaigneau V, Salis A, Lacomblez L, Benel L, Rascol O; French NS-Park/F-CRIN Network.

Parkinsonism Relat Disord. 2019 Mar;60:51-56. doi: 10.1016/j.parkreldis.2018.10.005. Epub 2018 Oct 4.

PMID:
30297210
16.

Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.

Fabbri M, Ferreira JJ, Lees A, Stocchi F, Poewe W, Tolosa E, Rascol O.

Mov Disord. 2018 Oct;33(10):1528-1539. doi: 10.1002/mds.27475. Epub 2018 Sep 27. Review.

PMID:
30264443
17.

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Charvin D, Medori R, Hauser RA, Rascol O.

Nat Rev Drug Discov. 2018 Nov;17(11):804-822. doi: 10.1038/nrd.2018.136. Epub 2018 Sep 28. Review. Erratum in: Nat Rev Drug Discov. 2018 Oct 12;:.

PMID:
30262889
18.

Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.

Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A.

Lancet Neurol. 2018 Sep;17(9):749-759. doi: 10.1016/S1474-4422(18)30239-4. Epub 2018 Jul 25.

PMID:
30055903
19.

Experience of care for Parkinson's disease in European countries: a survey by the European Parkinson's Disease Association.

Schrag A, Khan K, Hotham S, Merritt R, Rascol O, Graham L.

Eur J Neurol. 2018 Dec;25(12):1410-e120. doi: 10.1111/ene.13738. Epub 2018 Aug 16.

PMID:
29939446
20.

Longitudinal analysis of impulse control disorders in Parkinson disease.

Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Lee PC, Brice A, Vidailhet M, Elbaz A; DIGPD Study Group.

Neurology. 2018 Jul 17;91(3):e189-e201. doi: 10.1212/WNL.0000000000005816. Epub 2018 Jun 20.

21.

Tamoxifen and the risk of Parkinsonism: a case/non-case study.

Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL.

Eur J Clin Pharmacol. 2018 Sep;74(9):1181-1184. doi: 10.1007/s00228-018-2496-3. Epub 2018 Jun 3.

PMID:
29862427
22.

Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, double-blind, placebo-controlled, crossover trial.

Micallef J, Dupouey J, Jouve E, Truillet R, Lacarelle B, Taillard J, Daurat A, Authié C, Blin O, Rascol O, Philip P, Mestre D.

Fundam Clin Pharmacol. 2018 Oct;32(5):558-570. doi: 10.1111/fcp.12382. Epub 2018 Jun 6.

PMID:
29752828
23.

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.

Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, Soares-da-Silva P.

Neurology. 2018 May 22;90(21):e1849-e1857. doi: 10.1212/WNL.0000000000005557. Epub 2018 Apr 25.

PMID:
29695590
24.

Pain in Parkinson's disease: facts and uncertainties.

Antonini A, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, Ferreira J, Martinez-Martin P, Trenkwalder C, Rascol O.

Eur J Neurol. 2018 Jul;25(7):917-e69. doi: 10.1111/ene.13624. Epub 2018 Apr 18. Review.

PMID:
29520899
25.

Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.

Perez-Lloret S, Rascol O.

J Neural Transm (Vienna). 2018 Aug;125(8):1237-1250. doi: 10.1007/s00702-018-1869-1. Epub 2018 Mar 7. Review.

PMID:
29511826
26.

MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy.

Péran P, Barbagallo G, Nemmi F, Sierra M, Galitzky M, Traon AP, Payoux P, Meissner WG, Rascol O.

Mov Disord. 2018 Apr;33(4):600-608. doi: 10.1002/mds.27307. Epub 2018 Feb 23.

PMID:
29473662
27.

Iron as a therapeutic target for Parkinson's disease.

Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group.

Mov Disord. 2018 Apr;33(4):568-574. doi: 10.1002/mds.27275. Epub 2018 Jan 30. Review. No abstract available.

PMID:
29380903
28.

Abnormal pain perception in patients with Multiple System Atrophy.

Ory-Magne F, Pellaprat J, Harroch E, Galitzsky M, Rousseau V, Pavy-Le Traon A, Rascol O, Gerdelat A, Brefel-Courbon C.

Parkinsonism Relat Disord. 2018 Mar;48:28-33. doi: 10.1016/j.parkreldis.2017.12.001. Epub 2017 Dec 8.

PMID:
29254664
29.

Combined cardiovascular and sweating autonomic testing to differentiate multiple system atrophy from Parkinson's disease.

Pavy-LeTraon A, Brefel-Courbon C, Dupouy J, Ory-Magne F, Rascol O, Senard JM.

Neurophysiol Clin. 2018 Apr;48(2):103-110. doi: 10.1016/j.neucli.2017.11.003. Epub 2017 Dec 14.

PMID:
29249575
30.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13. Review.

31.

L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.

Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Rascol O; of the COPARK Study Group.

Eur J Neurol. 2017 Dec;24(12):1532-1538. doi: 10.1111/ene.13466. Epub 2017 Oct 9.

PMID:
28940893
32.

Critical appraisal of clinical trials in multiple system atrophy: Toward better quality.

Castro Caldas A, Levin J, Djaldetti R, Rascol O, Wenning G, Ferreira JJ; Movement Disorders Society MSA Study Group.

Mov Disord. 2017 Oct;32(10):1356-1364. doi: 10.1002/mds.27080. Epub 2017 Aug 7. Review.

PMID:
28782838
33.

New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.

Thibault L, Rascol O, Corvol JC, Ferreira J, Defebvre L, Deplanque D, Bordet R, Moreau C, Devos D.

Mov Disord. 2017 Oct;32(10):1365-1370. doi: 10.1002/mds.27055. Epub 2017 Jul 13. Review. No abstract available.

PMID:
28703395
34.

Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes.

Thu Trang D, Cool C, Laffon de Mazieres C, Lapeyre-Mestre M, Montastruc JL, Rascol O, Rolland Y, Sommet A.

J Am Med Dir Assoc. 2017 Sep 1;18(9):791-796. doi: 10.1016/j.jamda.2017.04.014. Epub 2017 Jun 13.

PMID:
28623157
35.

Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.

Lees AJ, Ferreira J, Rascol O, Reichmann H, Stocchi F, Tolosa E, Poewe W.

Expert Rev Neurother. 2017 Jul;17(7):649-659. doi: 10.1080/14737175.2017.1336086. Epub 2017 Jun 5. Review.

PMID:
28580819
36.

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.

Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ; Preladenant Early Parkinson Disease Study Group.

Neurology. 2017 Jun 6;88(23):2198-2206. doi: 10.1212/WNL.0000000000004003. Epub 2017 May 10.

PMID:
28490648
37.

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P; BIPARK-2 Study Investigators.

JAMA Neurol. 2017 Feb 1;74(2):197-206. doi: 10.1001/jamaneurol.2016.4703.

PMID:
28027332
38.

Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.

Montastruc F, Moulis F, Araujo M, Chebane L, Rascol O, Montastruc JL.

Eur J Clin Pharmacol. 2017 Jan;73(1):99-103. doi: 10.1007/s00228-016-2142-x. Epub 2016 Oct 27.

PMID:
27796464
39.

Characterization of Burning Mouth Syndrome in Patients with Parkinson's Disease.

Bonenfant D, Rompré PH, Rei N, Jodoin N, Soland VL, Rey V, Brefel-Courbon C, Ory-Magne F, Rascol O, Blanchet PJ.

J Oral Facial Pain Headache. 2016 Fall;30(4):318-322. doi: 10.11607/ofph.1691.

PMID:
27792799
40.

A genome-wide association study in multiple system atrophy.

Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, Lees A, Ross OA, Dickson DW, Mok K, Mencacci NE, Schottlaender L, Chelban V, Ling H, O'Sullivan SS, Wood NW, Traynor BJ, Ferrucci L, Federoff HJ, Mhyre TR, Morris HR, Deuschl G, Quinn N, Widner H, Albanese A, Infante J, Bhatia KP, Poewe W, Oertel W, Höglinger GU, Wüllner U, Goldwurm S, Pellecchia MT, Ferreira J, Tolosa E, Bloem BR, Rascol O, Meissner WG, Hardy JA, Revesz T, Holton JL, Gasser T, Wenning GK, Singleton AB, Houlden H; European Multiple System Atrophy Study Group and the UK Multiple System Atrophy Study Group.

Neurology. 2016 Oct 11;87(15):1591-1598. Epub 2016 Sep 14.

41.

An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.

Nguyen TT, Pariente A, Montastruc JL, Lapeyre-Mestre M, Rousseau V, Rascol O, Bégaud B, Montastruc F.

Br J Clin Pharmacol. 2017 Mar;83(3):612-622. doi: 10.1111/bcp.13145. Epub 2016 Nov 6.

42.

Pharmacological Insights into Levodopa-induced Motor Fluctuations in Patients with Parkinson's Disease.

Rascol O.

Mov Disord Clin Pract. 2016 Sep 4;3(6):523-526. doi: 10.1002/mdc3.12389. eCollection 2016 Nov-Dec. No abstract available.

43.

Long-term effects of rasagiline and the natural history of treated Parkinson's disease.

Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW; AFU Investigators.

Mov Disord. 2016 Oct;31(10):1489-1496. doi: 10.1002/mds.26724.

PMID:
27431201
44.

Unmasking levodopa resistance in Parkinson's disease.

Nonnekes J, Timmer MH, de Vries NM, Rascol O, Helmich RC, Bloem BR.

Mov Disord. 2016 Nov;31(11):1602-1609. doi: 10.1002/mds.26712. Epub 2016 Jul 19. Review.

PMID:
27430479
45.

Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Perez-Lloret S, Rascol O.

CNS Drugs. 2016 Aug;30(8):703-17. doi: 10.1007/s40263-016-0360-5. Review.

PMID:
27344665
46.

French consensus procedure for assessing cognitive function in Parkinson's disease.

Dujardin K, Auzou N, Lhommée E, Czernecki V, Dubois B, Fradet A, Maltete D, Meyer M, Pineau F, Schmitt E, Sellal F, Tison F, Vidal T, Azulay JP, Welter ML, Corvol JC, Durif F, Rascol O; NS-Park network.

Rev Neurol (Paris). 2016 Nov;172(11):696-702. doi: 10.1016/j.neurol.2016.05.001. Epub 2016 Jun 16.

PMID:
27318613
47.

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.

Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.

PMID:
27214664
48.

Atropinic (Anticholinergic) Burden in Parkinson's Disease.

De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F.

Mov Disord. 2016 May;31(5):632-6. doi: 10.1002/mds.26595. Epub 2016 Mar 29. Review.

PMID:
27028036
49.

Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials.

Ferreira JJ, Mestre T, Guedes LC, Coelho M, Rosa MM, Santos AT, Barra M, Sampaio C, Rascol O.

Front Neurol. 2016 Mar 8;7:27. doi: 10.3389/fneur.2016.00027. eCollection 2016.

50.

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.

Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569. Epub 2016 Mar 15.

PMID:
26990766

Supplemental Content

Loading ...
Support Center